PDCD1 and neoplasm: Moreover, bintrafusp alfa may elicit a stronger and more durable anti-tumor response (ORR, 28.2–33%; mDoR, 2.8–30.4 months) than PD-1 inhibitors (nivolumab or pembrolizumab; ORR, 12–24%) in the treatment of HPV+ tumors [191, 192].